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Mouse models for cancer are revealing novel cancer-promoting roles for autophagy. Autophagy
promotes tumor growth by suppressing the p53 response, maintaining mitochondrial function,
sustaining metabolic homeostasis and survival in stress, and preventing diversion of tumor
progression to benign oncocytomas.Introduction
Macroautophagy (autophagy hereafter) is a highly conserved
pathway that degrades and recycles proteins and organelles to
generate nucleotides, amino acids, fatty acids, sugars, and
ATP to support metabolism and survival in starvation
(Rabinowitz andWhite, 2010). Autophagy also eliminates protein
aggregates and damaged organelles to maintain protein and
organelle quality (Mizushima and Komatsu, 2011). Autophagy
is thought to play a dual role in cancer, where it can prevent
tumor initiation by suppressing chronic tissue damage, inflam-
mation, and genome instability via its quality control function or
can sustain tumor metabolism, growth, and survival via nutrient
recycling (White, 2012). Determining the contextual role of auto-
phagy in cancer is therefore important, and the use of genetic
engineered mouse models (GEMMs) in this regard is becoming
increasingly useful.
Autophagy Prevents Tissue Damage and Maintains
Genome Stability
Autophagy mitigates oxidative stress by removing damaged
mitochondria, a key source of reactive oxygen species (ROS).
A deficiency in essential autophagy genes (Atgs) causes the
accumulation of defective mitochondria, excess ROS, DNA
damage, and genome instability (Mathew et al., 2007, 2009).
Autophagy may suppress DNA damage induced by ROS and
may have other roles in enabling DNA repair. Nucleotide
depletion promotes genome damage (Bester et al., 2011), and
autophagy may supply nucleotides for DNA replication and
repair through its recycling function (Rabinowitz and White,
2010). Autophagy has also been implicated in the timely
degradation of Sae2/CtIP in response to histone deacetylase
inhibition, a protein involved in homologous recombination
(HR)-mediated DNA repair (Robert et al., 2011).
Defects in autophagy lead to aberrant accumulation of
damaged organelles and proteins, particularly the autophagy
receptor and substrate p62 and the antioxidant transcription
factor NRF2. Their deregulation can induce chronic tissue
damage and inflammation (Komatsu et al., 2010; Mathew
et al., 2009). These activities may explain why mice with allelic
loss of the essential autophagy gene Atg6/Beclin1 are prone
to liver tumors and why those with mosaic deletion of Atg5 or1216 Cell 155, December 5, 2013 ª2013 Elsevier Inc.liver-specific deletion of Atg7 develop benign liver hepatomas
(Takamura et al., 2011). Loss of p62 reduces liver damage
and hepatoma formation resulting from autophagy deficiency,
indicating that aberrant accumulation of p62 is largely the cause
(Komatsu et al., 2010; Takamura et al., 2011). In these contexts,
autophagy likely plays a tumor-suppressive role, but whether
this occurs in human cancer remains to be determined. As
autophagy defects are genotoxic, it is possible that this impacts
the growth of tumors with compromised DNA repair.
Autophagy Promotes Mammary Tumorigenesis
Germline mutations in BRCA1, BRCA2, and PALB2 predispose
to hereditary breast cancer. These proteins function together
to maintain genome stability by promoting faithful repair of
double-strand breaks via HR (Moynahan and Jasin, 2010), and
the genome instability from their loss likely drives tumorigenesis.
BRCA1 and PALB2 also promote the NRF2-mediated antioxi-
dant defenses (Gorrini et al., 2013; Ma et al., 2012), suggesting
that oxidative stress elicited by the loss of BRCA1 or PALB2
may limit proliferation, thereby preventing tumorigenesis. The
TP53 gene encoding p53 is the most commonly mutated gene
in human cancers and is a DNA damage response regulator,
and overcoming p53-induced cell-cycle arrest, senescence,
and cell death is critical for tumorigenesis. Progression of
HR-deficient and most, if not all, other tumors is facilitated by
inactivation of p53 or its regulatory pathways. Similar to Brca1
and Brca2, mammary epithelial cell-specific knockout of Palb2
causes mammary tumorigenesis with long latency, and tumors
contain mutations in Trp53 (Huo et al., 2013). Combined ablation
of Palb2 and Trp53 accelerates tumorigenesis, establishing that
p53 is a barrier to Palb2-associated mammary tumor growth
(Figure 1A). Partial autophagy impairment due to allelic loss of
Beclin1 increases apoptosis and significantly delays mammary
tumor development following PALB2 loss but only when p53 is
present (Huo et al., 2013). Thus, autophagy promotes mammary
tumor growth by suppressing p53 activation induced by DNA
damage (Figure 1A).
These findings suggest that autophagy inhibition may be a
valid approach for the therapy of HR-deficient breast cancers,
but they also raise additional questions. Given the shared
functions of BRCA1, BRCA2, and PALB2, do autophagy defects
Figure 1. Role of Autophagy in Tumor Progression and Fate
(A) Autophagy promotes mammary tumorigenesis induced by PALB2 loss.
(B) Autophagy promotes the growth of KRASG12D-driven NSCLC. Lipid droplets are indicated in red, oncocytes are indicated in pink, and defective mitochondria
are indicated in yellow.
(C) Autophagy promotes BRAFV600E-induced lung tumor growth.also suppress mammary tumor development driven by loss of
BRCA1 and BRCA2? Is the defective tumorigenesis caused
by allelic loss of Beclin1 due to autophagy impairment or an
autophagy-independent function of Beclin1? The consequences
of deleting other essential autophagy genes on tumorigenesis
in this context should be tested. Whether complete rather than
partial autophagy defect reveals p53-independent autophagy
dependence of PALB2-deficient tumors also remains to be
determined. As inhibiting autophagy may be useful in the setting
of HR-deficiency with p53 intact, will it also be efficacious in
combination with inhibitors of HR in repair-proficient tumors?
Finally, will cancers with deficiencies in other DNA repair mech-
anisms also be sensitized to autophagy inhibition?
KRAS-Driven Cancers Are Addicted to Autophagy
Basal autophagy levels are low in normal, fed cells. RAS-driven
cancer cells have high levels of autophagy to maintain mito-
chondrial function for their metabolic needs (Guo et al., 2011).
Lack of Atg5 or Atg7 in KRAS-transformed cells causes accu-
mulation of morphologically abnormal mitochondria. In contrast
to KRAS-transformed cells that are autophagy proficient,
those that are autophagy deficient fail to maintain levels of
tricarboxylic acid cycle (TCA) metabolites and mitochondrialrespiration upon nutrient starvation, which creates an energy
crisis incompatible with survival (Guo et al., 2011; Yang et al.,
2011). Autophagy deficiency also impairs the tumorigenicity
of KRAS-transformed cells and human cancer cell lines with
activating mutations in KRAS, thereby playing a critical role in
sustaining the mitochondrial metabolism and stress tolerance
of these cancers.
Autophagy Dictates Lung Tumor Fate
In GEMMs for lung cancer, sporadic activation of an oncogenic
allele of Kras (KrasG12D) results in tumor initiation and gradual
progression to adenomas and adenocarcinomas upon acquisi-
tion of Trp53 mutations. Deletion of Atg7 dramatically alters
the progression of these tumors, producing the accumulation
of defective mitochondria, accelerated induction of p53, and
proliferative arrest. Without ATG7, tumors develop into oncocy-
tomas instead of adenomas and carcinomas, proliferation is
suppressed, and tumor burden is reduced (Figure 1B) (Guo
et al., 2013).
Oncocytomas are a rare, predominantly benign tumor type
signified by the accumulation of respiration-defective mitoc-
hondria attributed to mitochondrial genomemutations and com-
pensatory mitochondrial biogenesis (Gasparre et al., 2011).Cell 155, December 5, 2013 ª2013 Elsevier Inc. 1217
Generation of oncocytomas upon loss of autophagy suggests
autophagy defects, and the failure to remove defective mito-
chondria can also produce oncocytomas. Importantly, auto-
phagy impairment can divert progression of adenomas and
carcinomas to a more benign tumor type (Guo et al., 2013).
Lung cancers thus require autophagy to remove damaged mito-
chondria in order to maintain their function. As such, autophagy
defects may be an underlying basis for the genesis of human
oncocytomas, and autophagy inhibition in lung cancer therapy
may suppress tumor growth and produce more benign disease.
Autophagy Addiction of BRAF-Driven Tumors
Atg7 deletion in GEMMs for BRAFV600E-driven lung cancer
initially stimulates tumor growth, but this is transient and is
attributed to increased mitochondrial oxidative stress. As Nrf2
deficiency in the BrafV600E lung tumors also promotes early
tumor growth, whereas combined loss of both Atg7 and Nrf2
shows no additional effect, the two genes may act by the
same mechanism (Figure 1C) (Strohecker et al., 2013). Nrf2
loss decreases the transcription of ROS detoxification genes,
and Atg7 loss prevents elimination of ROS-producing mito-
chondria; thus, increased ROS may transiently stimulate the
proliferation of newly forming tumors. Over time, Atg7 deficiency
causes accumulation of defective mitochondria and accelerates
p53 induction and growth arrest. Ultimately, Atg7 deficiency, like
Nrf2 deficiency, impairs tumorigenesis. Thus, BRAFV600E-driven
lung tumors are also addicted to autophagy (Strohecker et al.,
2013).
One interesting distinction between the roles of autophagy in
KRAS-driven compared to BRAF-driven lung tumors relates to
the survival of the mice. Autophagy deficiency reduces tumor
burden in both settings when p53 was present, but overall
mouse survival is only increased with activated BRAF (Stro-
hecker et al., 2013). Autophagy-deficient Kras lung tumors cause
mice to die of pneumonia instead of cancer (Figure 1B and C)
(Guo et al., 2013), which may be due to autophagy defects
promoting inflammation (Deretic, 2011).
Autophagy Suppresses the Ability of p53
to Limit Tumor Growth
In both KRAS and BRAF lung tumors, removal of p53 greatly
accelerates progression to adenocarcinomas; however, the
loss of Atg7 still retains some antiproliferative effect (Figure 1B
and C). This is in contrast to the Palb2-deficient tumors in which
allelic loss of Beclin1 has no effect in the absence of p53.
Whether autophagy works through p53-dependent or -indepen-
dent mechanisms depends therefore upon the mutagenic
drivers of tumor growth. For example, loss of PALB2 and HR
may directly activate p53 and the DNA damage response by
causing DSBs, whereas loss of KRAS and BRAF does not
impinge upon a similar response.
Autophagy Relieves Dependence on Glutamine
Atg7-deficient tumor cells derived from KRASG12D-driven or
BRAFV600E-driven lung cancers display less mitochondrial
respiration and are sensitized to starvation-induced cell death
(Guo et al., 2013; Strohecker et al., 2013). Thus, maintaining
functional mitochondria by upregulating autophagy might be1218 Cell 155, December 5, 2013 ª2013 Elsevier Inc.one survival strategy for autophagy-addicted cancers. This
sensitivity to starvation conferred by loss of autophagy is
rescued by glutamine supplementation (Guo et al., 2013; Stro-
hecker et al., 2013). Autophagy may provide amino acids via
protein degradation to replenish TCA cycle intermediates,
enable glutamine usage for NADPH production and redox
balance, and suppress senescence (White, 2013). Although
RAS-driven cancers can acquire glutamine by consuming and
digesting extracellular albumin through macropinocytosis,
autophagy may provide an alternative glutamine supply critical
in the absence of accessible extracellular protein and amino
acids (White, 2013).
AutophagyMaintains Lipid Homeostasis in KRAS-Driven
Tumors with p53 Loss
A unique feature of autophagy-deficient p53 null KRAS lung
cancers is the striking accumulation of lipids (Guo et al., 2013).
In the absence of p53, autophagy is required to maintain mito-
chondrial fatty acid oxidation (FAO), and without autophagy,
tumor cells contain mitochondria that fail to respire when pro-
vided a lipid substrate (Guo et al., 2013). p53 deficiency alters
metabolism to promote lipid storage (Cheung and Vousden,
2010; Zhu and Prives, 2009). If lipid catabolism by FAO signifi-
cantly contributes to the metabolism of these p53-deficient
tumors, preservation of mitochondrial function through mito-
phagy may be essential for lipid degradation, utilization, and
homeostasis. Furthermore, lipid accumulation due to autophagy
ablation does not occur in BRAFV600E-induced lung tumors
(Strohecker et al., 2013), indicating a fundamental difference of
lipid metabolism and perhaps also utilization of mitochondria
among lung tumors driven by different oncogenes.
Why Is Autophagy Addiction Partly p53 Dependent?
Autophagy suppresses the p53 response likely by limiting DNA
damage, oxidative stress, or other aspects of oncogene activa-
tion, thereby alleviating an important cell-cycle checkpoint that
impedes tumorigenesis. How then may autophagy limit p53
function? p53 is a key checkpoint regulator, and its abundance
and activity increase following DNA damage and a myriad of
other stressors. Autophagy is also a protective response to
stress and prevents genome damage. Loss of PALB2 and the
resulting ROS and DNA damage can trigger p53 activation that
may be further enhanced by loss of the protective function of
autophagy. The same may also hold true for oncogenic KRAS
and BRAF because they can cause DNA replication stress
that may be further augmented by autophagy deficiency.
Alternatively, autophagy may degrade p53 and limit its accumu-
lation (Korolchuk et al., 2009). This, however, seems unlikely
because autophagy deficiency causes genome instability even
in the absence of p53, suggesting that it is suppressing the
occurrence of DNA damage rather than the response to it
(Mathew et al., 2007).
Once induced, p53 can activate the transcription of genes in
the autophagy pathway and promote autophagy (Crighton
et al., 2006; Kenzelmann Broz et al., 2013). Autophagy induction
by p53 may be a negative feedback mechanism to turn down
p53 function. A failure to limit p53 in autophagy-deficient cells
may be cytotoxic.
Another explanation for this dependence may relate to their
roles in metabolism. p53 loss promotes glycolysis and sup-
presses respiration (Cheung and Vousden, 2010), which reduces
ROS that may require mitigation by autophagy to limit DNA
damage, growth arrest, senescence, and apoptosis. Thus, the
absence of p53 can render autophagy less important. Auto-
phagy also provides metabolic substrates to support cellular
metabolism (Rabinowitz and White, 2010). Autophagy may
supply nucleotides for efficient DNA repair or may otherwise
promote the function of the DNA repair machinery, lessening
p53 activation. Determining the mechanism by which autophagy
modulates the DNA damage response and DNA repair pathways
and vice versa is important.
Exploiting Autophagy Inhibition in Cancer Therapy
These recent findings that autophagy promotes tumorigenesis
support the concept of autophagy inhibition as a potential
approach to cancer prevention and treatment. Given that
autophagy supplies metabolic substrates essential for cancer
cell survival, identification of the exact substrates that are pro-
vided and the processes they support may also reveal novel
targets for cancer therapy.
As with Palb2 mutation, blocking autophagy may prevent the
development or slow the progression of BRCA1- and BRCA2-
associated breast cancers and perhaps other cancers whose
etiology involves defective DNA repair and ROS overproduction.
Moreover, blocking mitophagy or targeting mitochondrial
metabolism might be a potential approach to compromise the
survival of KRAS- or BRAF-driven lung cancers. Additionally,
targeting FAO may be applied to KRAS-driven lung cancers
with p53 inactivation. Autophagy inhibition may also be valuable
in combination with other anticancer therapeutic approaches
(White, 2012).
For optimal use of autophagy inhibition in cancer therapy,
additional issues need to be addressed. For example, would
autophagy inhibition in established tumors lead to oncocytomas
and suppressed growth? How long does it take for autophagy
inhibition to suppress the growth of established tumors?
Is autophagy inhibition selectively detrimental to tumors com-
pared to normal tissue? Are the detrimental consequences of
autophagy ablation reversible in tumor versus normal tissue,
and is this applicable to human tumors? More importantly,
what happens if autophagy is restored in autophagy-deficient
tumors? These questions are readily addressable and will guide
us moving forward.
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